Verzenio (abemaciclib) has just gained its first approval in HR+/HER2- metastatic breast cancer, but the failure in non-small cell lung cancer (NSCLC) limits the drug's growth options.

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

These patients were then randomized into three equal groups to receive imlunestrant monotherapy, a combination of imlunestrant and Lilly’s blockbuster breast cancer drug Verzenio (abemaciclib ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Notably, these two drugs combined generated $4.37 billion in total revenue in Q3, trailing only Verzenio ($1.4 billion for advanced or metastatic breast cancer) and Trulicity ($1.3 billion for ...

Lilly’s current offerings include Verzenio for early and metastatic breast cancers. Verzenio, which Lilly has heavily advertised in recent years, is a top seller for Lilly, with sales of almost ...